Long non-coding RNA SNHG15 in various cancers: a meta and bioinformatic analysis

Abstract

Background The snoRNA host gene SNHG15 produces a long non-coding RNA (lncRNA) with a short half-life and has been reported to be dysregulated in multiple cancers and has recently been found to be correlated with tumour progression. Therefore, this meta-analysis was performed to evaluate the generalised prognostic role of small nucleolar RNA host gene 15 (SNHG15) in malignancies, based on variable data from different studies. Methods Four public databases were used to identify eligible studies. The association between prognostic indicators and clinical features was extracted and pooled to estimate the hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs). Publication bias was measured using Begg’s test and Egger’s test, and the stability of pooled results were measured using sensitivity analysis. Additionally, an online database based on The Cancer Genome Atlas (TCGA) was screened to further validate our results. Ultimately, we predicted the molecular regulation of SNHG15 based on the public databases. Results In total, 11 studies including 1087 patients were ultimately enrolled in our meta-analysis. We found that SNHG15 overexpression was associated with worse overall survival (OS) and disease-free survival (DFS), and this was validated in the Gene Expression Profiling Interactive Analysis (GEPIA) cohort. Moreover, increased SNHG15 expression suggested advanced TNM stage and LNM, but was not associated with age, gender, or tumour size. No publication bias or instability of the results was observed. SNHG15 was significantly upregulated in seven cancers and elevated expression of SNHG15 indicated shorter OS and DFS in five malignancies based on the validation using the GEPIA cohort. Further functional prediction indicated that SNHG15 may participate in some cancer-related pathways. Conclusions Upregulation of lncRNA SNHG15 was notably associated with worse prognosis and clinical features, suggesting that SNHG15 might serve as a novel prognostic factor in various cancers.

LncRNA HCP5 as a potential therapeutic target and prognostic biomarker for various cancers: a meta‑analysis and bioinformatics analysis

“…Accumulating studies have shown that lncRNAs were abnormally expressed in various cancers, and function as oncogene or tumor suppressor based on these expression level, participate in the initiation and progression of cancer. Previous meta-analyses have indicated that DLX6-AS1 [ 40 ], PVT1 [ 41 ], SNHG15 [ 22 ] and GHET1 [ 24 ] are related to the clinicopathological features and prognosis of various cancers. These evidences indicated that lncRNA may be a specific prognostic biomarker and therapeutic target for cancer.…”

“…The total scores for different studies ranged from 0 to 9. The study was considered to be high quality if the score was > 6 [ 22 ].…”

Non-Coding RNAs in Pancreatic Cancer Diagnostics and Therapy: Focus on lncRNAs, circRNAs, and piRNAs

“…SNHG15 is an lncRNA which plays critical roles in the development and progression of various cancers through regulation of Akt/mTOR signaling [153,154]. It has been reported as a prognostic marker in colorectal and liver cancers [155,156].…”

The Role of SNHG15 in the Pathogenesis of Hepatocellular Carcinoma

“…When SNHG15 is produced in higher quantities, it is associated with tumorigenic functions, including proliferation and metastasis in a variety of cancer types [ 22 , 23 , 24 ]. SNHG15 has been linked to lower survival in a lot of human malignancies, including breast cancer, colorectal cancer, gastric cancer, glioma, hepatocellular cancer, lung cancer, osteosarcoma, ovarian cancer, pancreatic cancer, renal cell carcinoma and thyroid cancer [ 25 , 26 ]. In pancreatic cancer tissue samples and cell lines, its expression was higher than expected, suggesting that it has pro-oncogenic functions [ 27 ].…”